Cargando…

Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis

Prostate cancer is a common cause of cancer death in men. In advanced stages of prostate cancer, androgen deprivation therapy (ADT) is initiated. Despite ADT, prostate cancers invariably progress to become androgen independent. A growing body of evidence implicates iron dysmetabolism in prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjerknes, Christian, Framroze, Bomi, Currie, Crawford, Pettersen, Caroline Hild Hakvåg, Axcrona, Karol, Hermansen, Erland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032914/
https://www.ncbi.nlm.nih.gov/pubmed/35447901
http://dx.doi.org/10.3390/md20040228
_version_ 1784692762257391616
author Bjerknes, Christian
Framroze, Bomi
Currie, Crawford
Pettersen, Caroline Hild Hakvåg
Axcrona, Karol
Hermansen, Erland
author_facet Bjerknes, Christian
Framroze, Bomi
Currie, Crawford
Pettersen, Caroline Hild Hakvåg
Axcrona, Karol
Hermansen, Erland
author_sort Bjerknes, Christian
collection PubMed
description Prostate cancer is a common cause of cancer death in men. In advanced stages of prostate cancer, androgen deprivation therapy (ADT) is initiated. Despite ADT, prostate cancers invariably progress to become androgen independent. A growing body of evidence implicates iron dysmetabolism in prostate cancer progression. A bioactive peptide-rich salmon protein hydrolysate (SPH) has previously been demonstrated to modulate iron homeostatic mechanisms. In the present study, the anticancer effect of SPH and bicalutamide co-treatment on LNCaP and PC3 prostate cancer cell proliferation was investigated. Our results found that SPH potentiates the anti-proliferative effect of bicalutamide in a dose-dependent manner for both cell lines. In the presence of 160 µg/mL SPH, co-treatment with 1.0 µM bicalutamide decreased LNCaP cells’ relative colony survival from 25% (1.0 µM bicalutamide monotreatment) to 2% after culturing for 12 days. For PC3 cells, the relative colony survival diminished from 52% (10.0 µM bicalutamide) to 32% at an SPH concentration of 160 µg/mL. Gene expression profiling, employing quantitative real-time PCR, revealed that the inhibitory effects were related to significant FTH1 up-regulation with a concomitant TFRC down-regulation. In conclusion, our results provide in vitro evidence that SPH potentiates the growth inhibitory effect of bicalutamide on prostate cancer cells by modulating iron homeostasis mechanisms.
format Online
Article
Text
id pubmed-9032914
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90329142022-04-23 Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis Bjerknes, Christian Framroze, Bomi Currie, Crawford Pettersen, Caroline Hild Hakvåg Axcrona, Karol Hermansen, Erland Mar Drugs Article Prostate cancer is a common cause of cancer death in men. In advanced stages of prostate cancer, androgen deprivation therapy (ADT) is initiated. Despite ADT, prostate cancers invariably progress to become androgen independent. A growing body of evidence implicates iron dysmetabolism in prostate cancer progression. A bioactive peptide-rich salmon protein hydrolysate (SPH) has previously been demonstrated to modulate iron homeostatic mechanisms. In the present study, the anticancer effect of SPH and bicalutamide co-treatment on LNCaP and PC3 prostate cancer cell proliferation was investigated. Our results found that SPH potentiates the anti-proliferative effect of bicalutamide in a dose-dependent manner for both cell lines. In the presence of 160 µg/mL SPH, co-treatment with 1.0 µM bicalutamide decreased LNCaP cells’ relative colony survival from 25% (1.0 µM bicalutamide monotreatment) to 2% after culturing for 12 days. For PC3 cells, the relative colony survival diminished from 52% (10.0 µM bicalutamide) to 32% at an SPH concentration of 160 µg/mL. Gene expression profiling, employing quantitative real-time PCR, revealed that the inhibitory effects were related to significant FTH1 up-regulation with a concomitant TFRC down-regulation. In conclusion, our results provide in vitro evidence that SPH potentiates the growth inhibitory effect of bicalutamide on prostate cancer cells by modulating iron homeostasis mechanisms. MDPI 2022-03-28 /pmc/articles/PMC9032914/ /pubmed/35447901 http://dx.doi.org/10.3390/md20040228 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bjerknes, Christian
Framroze, Bomi
Currie, Crawford
Pettersen, Caroline Hild Hakvåg
Axcrona, Karol
Hermansen, Erland
Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis
title Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis
title_full Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis
title_fullStr Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis
title_full_unstemmed Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis
title_short Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis
title_sort salmon protein hydrolysate potentiates the growth inhibitory effect of bicalutamide on human prostate cancer cell lines lncap and pc3 by modulating iron homeostasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032914/
https://www.ncbi.nlm.nih.gov/pubmed/35447901
http://dx.doi.org/10.3390/md20040228
work_keys_str_mv AT bjerkneschristian salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis
AT framrozebomi salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis
AT curriecrawford salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis
AT pettersencarolinehildhakvag salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis
AT axcronakarol salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis
AT hermansenerland salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis